Krstevska, Valentina
Preferred name
Krstevska, Valentina
Official Name
Krstevska, Valentina
Main Affiliation
Email
valentina.krstevska@medf.ukim.edu.mk
32 results
Now showing 1 - 10 of 32
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Фактори кои влијаат врз преживувањето кај постоперативно ирадирани болни со малигни астроцитоми на мозокот(Македонски лекарско друштво, 2002); ; Kraleva, Silvana - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prognostic factors in patients with recurrent head and neck cancer treated with reirradiation(2008); ; ; The aim of this study was to determine the prognostic factors concerning overall survival (OS) and progression- free survival (PFS) following reirradiation in patients with recurrent squamous cell head and neck cancer (HNC). - Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Функционални реакции на хипофарингеалната мукоза индуцирани со радиотерапија(Македонско лекарско друштво, 2002); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Radical radiotherapy for squamous cell carcinoma of the larynx - comparison of three-dimensional conformal radiotherapy with cobalt-60 teletherapy(2011); ; The aim of the study was to report the results of radical radiotherapy performed by three-dimensional conformal radiotherapy (3DCRT) for squamous cell carcinoma of the larynx and to compare these data with those obtained with two-dimensional radiotherapy (2DRT) realized with cobalt-60 teletherapy i.e. telecobalt therapy (TCT). Eighty patients with previously untreated laryngeal cancer were irradiated with curative intent at the University of Radiotherapy and Oncology Clinic (UCRO) in Skopje between February 1999 and December 2008. Radical radiotherapy with the TCT unit was performed on 38 patients between February 1999 and May 2005. From June 2005 to December 2008, 42 patients were treated with a linear accelerator using 3DCRT. Complete response rates three months after completion of radiotherapy were 84.2% (32 of 38) and 92.6% (39 of 42) in the group irradiated with TCT unit and in the group treated with 3DCRT, respectively. No statistically significant differences were observed either in locoregional control (LRC) or overall survival (OS) between the patients treated with two different radiotherapy techniques. The grade of acute reactions of the skin and the larynx differed significantly between the accomplished radiotherapy techniques (Nonparametric Mann-Whitney U Test; U=577.0; Z=-2.129; p=0.012, and U=497.0; Z=-2.90; p=0.001, respectively). There were statistically significant differences observed in the grade of late effects in the skin and in the subcutaneous tissue between the radiotherapy techniques used (Nonparametric Mann-Whitney U Test; U=425.0; Z=-3.593; p=0.001 and U=637.0; Z=-1.551; p=0.035, respectively). According to the confirmed advantage of 3DCRT in terms of reduced treatment toxicity observed in our study, we consider conformal techniques being a basis in definitive radiotherapy of squamous cell carcinoma of the larynx until the new revolutionary techniques will be clinically available. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Акутниот мукозитис во усната празнина и во орофаринксот при радиотерапијата на планоцелуларниот карцином на ларинксот, орофаринксот и хипофаринксот(Македонско лекарско друштво, 2002); ; ; Stefanovski, Zoran - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Постоперативна радиотерапија со ограничен зрачен волумен во третманот на малигните астроцитоми на мозокот(Македонско лекарско друштво, 2003); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: our experience(2009-12); The aim of the study was to compare the survival impact of concurrent versus sequential treatment with radiotherapy and chemotherapy in inoperable stage III non-small cell lung cancer (NSCLC). 85 patients were randomly assigned to one of the two treatment groups. In the sequential group, 45 patients had previously received sequential chemotherapy with 4 cycles of carboplatine and etoposide followed by conformal radiotherapy (RT). In the second concurrent group 40 patients received concomitant chemotherapy of cisplatine and etoposide and conformal RT followed by two cycles of consolidation chemotherapy of carboplatine and etoposide. We described all phases of the conformal three dimensional (3-D) RT. From November 2005 to October 2008, 93 patients were enrolled. Eight patients were not eligible, seven had stage IV and one had pleural effusion. All these were initially considered to have stage IIIB disease. The median survival was 13 months for the patients in the sequential group and 22 months in the concurrent treatment group. The difference was statistically significant (log-rank test p = 0.001). The disease-free survival was 9 months in the sequential group and 17 months in the concurrent treatment group. The difference was statistically significant (log-rank test p = 0.001) The 1- and 2-year survival rates were 73.6% and 39.7% in the concurrent group and 54.9% and 13.7% in the sequential group, respectively (log-rank test, p = 0.0011). Treatment-related toxicities were assessed according the RTOG/EORTC criteria. Acute esophagitis and incidence of neutropenia were higher with the concurrent than with the sequential treatment. Grade 3 esophagitis was characteristic only of concurrent treatment and it was a reason for radiotherapy interruption, but no longer than 7 days. Secondary anaemia was more frequent in the sequential treatment group. The statistical significant differences in survival suggest that concurrent chemotherapy and conformal three-dimensional radiotherapy is the optimal strategy for patients with locally advanced NSCLC. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Concurrent radiochemotherapy in advanced hypopharyngeal cancer(2010-05-18); ; Concurrent platinum-based radiochemotherapy has been recommended as a standard of care in patients with locally advanced squamous cell head and neck carcinomas. Unfortunately, there is a lack of level one evidence on best treatment approach for advanced hypopharyngeal cancer. This report aims to summarize the results of our study on concurrent radiochemotherapy in patients with advanced hypopharyngeal cancer. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Use of analgesics in patients affected by head & neck malignancy during palliative radiotherapy(2003); ; ; Stojmenova, VitaBackground: Treating the Head & Neck malignancy failure after surgery and radiotherapy (RT) is still a problem. The roles of reirradiation and chemotherapy are palliative. These patients (pts) suffered from moderate to sever pain that was less responsive to opioid therapy. The aim of this study was to evaluate efficiency among tramadol and amitriptyline in head & neck cancer pts with moderate pain during palliative RT. Material and Methods: 30 pts (21 M, 9 F) affected by head & neck metastatic disease in lymph nodes, failure after primary therapy. All pts included presented moderate pain defined as VAS between 5–7, and were under NSAIDs treatment and palliative RT. 15 pts (group A) used tramadol with initial dose 200 mg/day, with doses escalated up to 300-400/day. Other 15 pts (group B) used amitriptyline with starting dose 10 mg in the elderly and 25 mg in younger pts with doses increased every few days, when doses have reached the effective range (e.g. 75–100 mg). Pain was measured according the linear VAS (0-10) at the start of and during the period and at the end of RT, including day 0, 7, 14 and 21. Results: There was a difference between groups in VAS evaluation, this was: 6.2, 5.3, 4.8, 4.9 at days 0, 7, 14, and 21 respectively for tramadol group-A and 6.1, 3.5, 1.7, 1.2, respectively for group-B. Percentage of pts under pain control (VAS <3) was registered only in group B in follow up visits (40.6% at day 7, 80% at day 14 and 86.6 % at day 21). Conclusions: Tricyclic antidepressant-amitripyline was significant efficiency pain treatment in head & neck cancer pts with moderated pain. Considering our results, we supposed that there is distinct mechanism that created neuropathic pain in the head & neck region. available by spring 2003. 74P